BioTuesdays
Avivagen

Avivagen closes private placement

Avivagen (TSX-V:VIV) has completed a private placement of brokered and non-brokered components, selling 60 million units for gross proceeds of $3.6-million. Each unit consists of one common share and one-half of a...

CymaBay Therapeutics

HCW downgrades CymaBay to neutral

H.C. Wainwright has downgraded CymaBay Therapeutics (NASDAQ:CBAY) to “neutral” from “buy” with a price target of $2.25. The stock closed at $2.44 on Tuesday. Yesterday, CymaBay discontinued its exploratory Phase 2 study...

ContraVir Logo

Maxim likes ContraVir merger with Ciclofilin

The merger of ContraVir Pharmaceuticals (NASDAQ:CTRV) with closely-held Ciclofilin Pharmaceuticals strengthens ContraVir’s position in the hepatitis B virus (HBV) space, according to a new report from Maxim Group...

Titan Pharmaceuticals Logo

Roth ups Titan Pharma price target to $10

Roth Capital Partners has raised its price target for Titan Pharmaceuticals (NASDAQ:TTNP) to $10 from $7.75 after the FDA approved Titan’s six-month Probuphine implant for the treatment of opioid addiction. The stock...

fibrocell

Roth resumes coverage of Fibrocell at buy

Roth Capital Partners has resumed coverage of Fibrocell Science (NASDAQ:FCSC) with a “buy” rating and $7 price target. The stock closed at $2.12 on Monday. Fibrocell leverages its expertise with fibroblasts to target...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.